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1 |  INTRODUCTION
The podocyte is critical to the proper functioning of the mam-
malian glomerular filtration barrier and the prevention of albu-
minuria, a hallmark of kidney disease. Therefore, identifying 
signaling molecules and pathways that regulate podocyte func-
tion and which can be pharmacologically targeted is important.
Glycogen synthase kinase 3 (GSK3) is a multi‐functional 
serine/threonine kinase which regulates a number of distinct 
signaling pathways.1 In mammals, GSK3 exists as two sepa-
rate but related isoforms (α and β) with overall homology of 
85% and highly conserved kinase domains (97% homology).2 
Because of this structural similarity, currently available GSK3 
inhibitors are not isoform selective. However, there is evi-
dence that GSK3α and β are not entirely redundant and have 
different functions: GSK3β null mice die during late embryo-
genesis as a result of impaired NFκB signaling and cardiac 
defects 3,4 whereas whole body GSK3α knockout mice are 
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Abstract
Podocytes are key cells in maintaining the integrity of the glomerular filtration bar-
rier and preventing albuminuria. Glycogen synthase kinase 3 (GSK3) is a multi‐func-
tional serine/threonine kinase existing as two distinct but related isoforms (α and 
β). In the podocyte it has previously been reported that inhibition of the β isoform 
is beneficial in attenuating a variety of glomerular disease models but loss of both 
isoforms is catastrophic. However, it is not known what the role of GSK3α is in these 
cells. We now show that GSK3α is present and dynamically modulated in podocytes. 
When GSK3α is transgenically knocked down specifically in the podocytes of mice 
it causes mild but significant albuminuria by 6 weeks of life. Its loss also does not 
protect in models of diabetic or Adriamycin‐induced nephropathy. In vitro deletion 
of podocyte GSK3α causes cell death and impaired autophagic flux suggesting it is 
important for this key cellular process. Collectively this work shows that GSK3α is 
important for podocyte health and that augmenting its function may be beneficial in 
treating glomerular disease.
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viable and interestingly, exhibit enhanced insulin sensitivity 
in a strain‐dependent manner.5 Multiple cell‐specific GSK3 
knockout mouse models have been described and indicate that 
the functions of the GSK3 isoforms are cell‐type dependent.6-9
We have recently shown that GSK3 is a crucial regulator 
of podocyte and kidney function and that simultaneous loss 
of both GSK3 isoforms in podocytes is highly detrimental.10 
Developmental deletion of GSK3 results in neonatal death as-
sociated with renal failure while knockout in mature podocytes 
leads to a spectrum of renal disease. We also showed that pro-
longed pharmacological inhibition of GSK3 in rats using lithium 
caused significant proteinuria with evidence of focal segmental 
glomerulosclerosis (FSGS).10 This is consistent with reports of 
FSGS and renal failure in patients on long‐term lithium therapy 
for conditions such as bipolar disorder.11,12 In contrast, a number 
of recent studies suggest that partial pharmacological inhibition 
of GSK3 as well as specific genetic knockout of the β isoform 
in podocytes can be beneficial in a number of experimental glo-
merular disease models including diabetic nephropathy, lupus 
nephritis and Adriamycin nephropathy.13-17 However, the role of 
podocyte GSK3α has received little consideration and it is not 
known whether this isoform has a specific role in podocyte ho-
meostasis or if its loss can also have a podocyte protective effect.
Given our interest in podocyte insulin signaling18 and the 
suggestion that specifically inhibiting GSK3α could enhance 
cellular insulin sensitivity we were keen to study the specific 
role of this GSK3 isoform in the podocyte. We therefore de-
veloped a mouse and podocyte cell model to do this.
We show here that reduced podocyte expression of 
GSK3α does not attenuate albuminuria in streptozotocin 
(STZ) diabetes or Adriamycin nephropathy models in mice. 
Moreover, near complete knockout of GSK3α in condition-
ally immortalized podocytes did not result in improved insu-
lin sensitivity or attenuation of Adriamycin induced injury. 
Conversely, we found that loss of podocyte GSK3α is mildly 
detrimental and reveal a role for this isoform in maintaining 
podocyte autophagic flux.
2 |  MATERIALS AND METHODS
2.1 | Murine insulin stimulation
Following an overnight fast, wild‐type mice were given an in-
traperitoneal injection of insulin (Novo Nordisk) at 1 unit/kg 
body weight (6  nmol/L). Mice were sacrificed after 10   
minutes and the kidneys snap frozen in liquid nitrogen.
2.2 | Immunofluorescence staining of 
kidney sections
Frozen kidneys were sectioned at 5  μm. Sections were 
blocked in phosphate buffered saline (PBS) containing 3% 
bovine serum albumin (BSA) and 0.3% triton X‐100 for 
1 hour, then incubated with primary antibodies overnight at 
4°C (pGSK3α 1:100; pGSK3β 1:100; nephrin 1:300; Wilm's 
tumor protein [WT‐1] 1:200). Following three PBS rinses, 
sections were incubated with fluorophore‐conjugated sec-
ondary antibodies (Life Technologies) for 1  hour at room 
temperature. Tissues were imaged using a Leica DM2000 
microscope and micrographs taken with Leica Application 
Suite. Image analysis was performed with ImageJ; all im-
ages were contrast enhanced using the same parameters.
2.3 | Insulin and Adriamycin stimulation of 
cultured podocytes
Conditionally immortalized mouse podocyte cell lines were 
used as previously described.19,20 Cells were serum starved 
for 4 hours then stimulated with insulin (Novo Nordisk) at 
10 nm and 100 nmol/L for 10 minutes.
For the Adriamycin injury model, cells were incubated with 
Adriamycin (Sigma) at the concentrations indicated for 24 hours.
2.4 | Western blotting
Cultured cells were lysed in radioimmunoprecipitation assay 
buffer supplemented with protease and phosphatase inhibitors 
(Sigma). Ten to thirty micrograms of protein was resolved by 
electrophoresis then transferred to a polyvinylidene difluoride 
membrane (Millipore). Membranes were blocked in TRIS‐
buffered saline with 0.1% tween 20 and 5% BSA for 1 hour 
then incubated overnight with primary antibody at a dilu-
tion of 1:1000. Membranes were washed before incubation 
with horseradish peroxidase conjugated secondary antibody 
(Sigma). Immunoreactive bands were visualized using Clarity 
ECL Western blotting substrate (Biorad) on a GE AI600 im-
ager. Densitometry was performed using ImageJ software.
2.5 | Mouse models
Mice in which exon two of GSK3α has been flanked by loxP 
sites5 were crossed with podocin Cre mice21 to generate po-
docyte‐specific GSK3α knockdown animals from embryonic 
day 12 (podGSK3αKD mice).
Diabetes was induced in mice at 6 weeks of age by intra-
peritoneal injection of STZ (Sigma) at 50 mg/kg body weight 
for five consecutive days. Mice injected with an identical vol-
ume of citrate buffer served as sham controls.
Adriamycin nephropathy was induced in mice at 8‐10 weeks 
of age by a single tail vein injection of Adriamycin (Sigma) at 
12 mg/kg body weight. These were studied for 2 weeks.
For STZ and Adriamycin models, mice were backcrossed 
for four generations onto a DBA2J strain background. Both 
sexes were studied.
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Transgenic mouse work was carried out in accordance 
with the University of Bristol's institutional guidelines and 
procedures approved by the United Kingdom (UK) Home 
Office in accordance with UK legislation.
2.6 | Podocyte primary culture
Glomeruli were isolated from podGSK3α KD and littermate 
control mice following dynabead perfusion as described 
previously.22 Glomeruli were plated out in Roswell Park 
Memorial Institute (RPMI) 1640 media supplemented with 
10% fetal bovine serum and 5% penicillin/streptomycin and 
incubated at 37°C. After 6  days, primary podocytes were 
harvested by trypsinization and cells were passed through a 
40 μm cell strainer to remove glomeruli.
2.7 | End point PCR
Mouse genotyping was performed using 5× PCRbio hs taq 
DNA polymerase (Insight) and the following primers:
Cre forward GTGCAACTTGAATAACCGGAAATGG
Cre reverse AGAGTCATCCTTACCGCCGTAAATCAAT
GSK3α forward CCCCCACCAAGTGATTTCACTGCTA
GSK3α reverse AACATGAAATTCCGGGCTCCAACTCTAT
RNA was isolated from podocyte primary cells using an Rneasy 
kit (Qiagen) and cDNA synthesized using a high capacity RNA 
to cDNA kit (Thermofisher Scientific). Primers used were:
WT‐1 forward GAGAGCCAGCCTACCATCC
WT‐1 reverse GGGTCCTGGTGTTTGAAGCAA
Platelet endothelial cell adhesion molecule‐1 (PECAM) for-
ward CAAGCAAAGCAGTGA
PECAM reverse AGCAGGACAGGTCCAACAAC
Platelet‐derived growth factor (PDGF) forward 
ACTTCTGTTGCTACACGAAGC
PDGF reverse CGGTTGAGTCAGTGGAGTCC
2.8 | Urinary albumin and creatinine 
measurements
Albumin and creatinine levels in mouse urine were measured 
using a mouse‐specific albumin ELISA (Bethyl) and creati-
nine companion kit (Exocell), following the manufacturers' 
methodology.
2.9 | Periodic acid Schiff staining
Kidneys were fixed in 10% buffered neutral formalin, further 
processed and paraffin embedded. Three micrometer sections 
were cut and stained using a Periodic acid Schiff staining kit 
(Sigma) according to the manufacturers' instructions. Tissues 
were imaged using a Leica DN2000 microscope and micro-
graphs taken using Leica Application Suite software. Image 
analysis was performed using ImageJ; all images were con-
trast enhanced using the same parameters.
Glomerulosclerosis was scored for each glomerulus as 
follows: 0 = normal glomeruli; 1 = up to 25% involvement; 
2  =  25%‐50% involvement; 3  =  50%‐75% involvement; 
4 = over 75% involvement. The glomerulosclerosis index 
was calculated according to the formula ([1 × N1] + [2 × 
N2] + [3 × N3] + [4 × N4])/(N0 + N1 + N2 + N3 + N4), 
where Nx is the number of glomeruli with each given score.
2.10 | Lentiviral transduction of a 
conditionally immortalized GSK3α floxed 
podocyte cell line
Kidneys were isolated from GSK3αfl/fl mice and used to 
make a temperature‐sensitive SV40 conditionally immor-
talized podocyte cell line as described previously.19 Cells 
were cultured at 33°C and when 50% confluent were trans-
duced with a lentivirus expressing Cre recombinase as 
described previously.10 Transduction was in RPMI media 
with hexadimethrine bromide (Sigma) at 4 μg/mL and the 
virus used at a multiplicity of infection of 1. Following 
a 24‐hour incubation, the lentivirus was removed and re-
placed with fresh media. Cells were thermo‐switched to 
38°C and incubated for a further 7 days before imaging and 
protein extraction.
To determine ciGSK3αKO cell number, cells were 
washed three times in PBS, the nuclei stained with Hoechst 
(Sigma) at 1 μg/mL and imaged using an IN Cell analyzer 
2200 (GE Healthcare) and data analyzed using IN Cell ana-
lyzer Developer software (GE Healthcare).
2.11 | Determination of podocyte number
Immunofluorescent analysis of mouse kidney sections 
was carried out as described above using a WT‐1 antibody 
(Abcam). 4′,6‐diamidino‐2‐phenylindole (DAPI) was used 
to counterstain nuclei. ImageJ software was used to count 
WT‐1 positive nuclei and expressed as a percentage of the 
total number of DAPI stained cells per glomerulus.
2.12 | Antibodies
Antibodies were obtained from Cell Signalling Technology: 
(pGSK3α [Ser 21] #9316; pGSK3β [Ser 9] #9323; total 
GSK3α/β #5676; total GSK3α #9338; pAKT [Ser 473] 
#4060; total AKT #4691; P‐p44/42 MAPK #4370; p44/42 
MAPK #4695); Acris (Nephrin #BP5030); Sigma (β‐actin 
clone AC‐15; GAPDH #G8795); Merck Millipore (WT‐1 
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clone 6F‐H2, used for western blotting), Abcam (WT‐1 
#89901) and Genetex (SV40 T antigen #134377).
2.13 | Statistics
Statistical analysis was performed using GraphPad Prism 
software. When comparing two groups t tests were used. 
When comparing more than two groups analysis of variance 
(ANOVA) was used. Statistical tests used and n numbers are 
shown in figure legends. Data are presented as the mean and 
error bars represent the standard error of the mean. P < 0.05 
was deemed statistically significant.
3 |  RESULTS
3.1 | Both GSK3α and GSK3β are 
phosphorylated in podocytes of murine 
glomeruli and in murine conditionally 
immortalized podocytes in response to insulin
We initially established that both GSK3α and GSK3β were 
expressed and dynamically regulated in the podocyte by 
studying wild‐type mice challenged with insulin after an 
overnight fast (Figure 1A,B). This revealed the rapid phos-
phorylation, and hence inactivation, of GSKα, at serine 21, 
and GSK3β, at serine 9, in the kidney. Both isoforms were 
phosphorylated in glomeruli and tubules. However, within 
the glomerulus phosphorylated GSK3 isoforms were highly 
enriched in the podocyte cell fraction. This was particularly 
clear for GSK3α as revealed by 3D reconstructive imaging 
of insulin treated glomeruli (Video S1). Western blotting 
of conditionally immortalized podocytes confirmed these 
phosphorylation findings in vitro (Figure 1C,D). Preliminary 
dose‐response experiments showed that our mouse podocyte 
cell line activated the PI3K pathway in response to insulin at 
1 nmol/L but this was more apparent at higher doses (Figure 
S1). Therefore, in subsequent experiments, cells were 
stimulated with insulin at 10 and 100  nmol/L. Although 
greater than the levels of insulin present in diabetic patients, 
10‐100 nmol/L is the standard dose used in the literature to 
elucidate insulin driven signaling pathways.23-28 Our in vivo 
studies were performed with insulin doses of 6 nmol/L.
3.2 | Generation of podocyte‐specific 
GSK3α knockdown mice
To study the effect of GSK3α deletion in podocytes we gen-
erated transgenic mice by crossing GSK3α floxed mice with 
mice expressing Cre recombinase under the control of a po-
docin promotor to confer podocyte specificity (Figure 2A). 
Genotypes of the progeny were confirmed using polymer-
ase chain reaction (PCR) (Figure 2B). Primary culture po-
docytes were also generated from podGSK3αKD mice and 
Cre negative control littermates and knockdown of GSK3α 
determined using Western blotting (Figure 2C, D). GSK3α 
expression was reduced by 50% in podGSK3αKD mice while 
GSK3β expression remained unchanged. We analyzed the 
purity of our primary cultures using sensitive PCR analysis 
of cDNA derived from the primary cultures. This revealed 
some expression of PECAM and PDGF (markers of glo-
merular endothelial and mesangial cells) in two of the Cre 
negative control samples, likely due to a small amount of glo-
merular contamination of the primary podocytes. However, 
in the GSK3αKD cells the cell population appeared to be pre-
dominantly of podocyte origin (Figure 2E). Finally, podocyte 
knockdown of GSK3α was confirmed by co‐staining kidney 
sections from podGSK3αKD and Cre negative control mice 
with total GSK3α and nephrin antibodies (Figure 2F).
3.3 | Podocyte‐specific 
knockdown of GSK3α does not ameliorate the 
progression of diabetic nephropathy in an STZ 
model of diabetes
Previous studies have shown improved insulin sensitivity and 
glucose handling in skeletal muscle cells of total body GSK3α 
knockout mice.5 Since podocytes are insulin responsive 
cells,29 we sought to determine whether podocyte‐specific 
deletion of GSK3α would ameliorate the progression of dia-
betic nephropathy in a mouse model of diabetes by improving 
insulin sensitivity. Diabetes was induced in podGSK3αKD 
mice and Cre negative control littermates by STZ administra-
tion at 6 weeks of age. Successful induction of diabetes was 
confirmed by measuring blood glucose at 4 weeks and hyper-
glycemia as well as body weight was identical in knockdown 
and control groups (Figure 3A,B). Urinary albumin creatinine 
ratio (uACR) was increased at 20 weeks in both knockdown 
and control groups after STZ induction with evidence of mild 
glomerulosclerosis on histological examination, but no statis-
tical differences were observed between them (Figure 3C,D) 
showing that the progression of diabetic nephropathy was not 
attenuated by podocyte GSK3α knockdown.
3.4 | Knockdown of GSK3α does not 
improve insulin sensitivity with respect to PI3 
kinase signaling
Podocyte GSK3α knockdown did not have a protective effect 
on the progression of STZ‐induced diabetic nephropathy but it 
is possible that this result was due to incomplete knockdown of 
GSK3α in our transgenic mouse model. To determine whether 
an increased level of GSK3α knockdown would be more ef-
fective in enhancing insulin sensitivity at a cellular/molecu-
lar level, we developed a temperature‐sensitive conditionally 
immortalized cell line from podocytes isolated from GSK3α 
floxed mice (Figure 4A). This cell line switched off the SV40 
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F I G U R E  1  GSK3α as well as β is phosphorylated in the podocyte in the murine glomerulus and in murine conditionally immortalized 
podocytes. (A, B) Immunofluorescent analysis of serine 21 phosphorylated GSK3α (A) and serine 9 phosphorylation of GSK3β (B) performed 
in mice that were fasted overnight and then given insulin (6 nmol/L) for 10 min. Podocyte‐specific phosphorylation of GSK3 (green) is shown 
by co‐localization with Nephrin (magenta)(white demonstrates co‐localization) arrowed in magnified images, scale bar = 25 μm. (C, D) Insulin 
increases inhibitory phosphorylation of GSK3 in conditionally immortalized murine podocytes. Representative blot (C) and densitometry shown 
(D). Unpaired t test, *P < 0.05; **P < 0.01, n = 3 experiments
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FIGURE 2  Generation of podocyte‐specific GSK3α knockdown mice. A, Breeding strategy used to generate podGSK3αKD mouse model showing 
deletion of GSK3α exon 2 in podGSK3αKD mice. B, Gel of end point polymerase chain reaction (PCR) products used to identify genotypes of podGSK3α 
mice. C, Western blot of podocyte primary culture cells from podGSK3αKD and littermate control mice. D, Densitometry of blot showing fold change of 
GSK3α and GSK3β levels normalized to GAPDH expression. Unpaired t test, **P < 0.01. podGSK3αKD podocytes have reduced expression of GSK3α. 
All primary podocytes express the podocyte marker WT‐1. E, Gel of end point PCR analysis of cDNA derived from podGSK3αKD and littermate control 
mice with WT‐1, PECAM and PDGF primers. Mouse kidney cDNA was used as a positive control. F, Immunofluorescent analysis of total GSK3α in 
podGSK3αKD and Cre negative control mice including co‐staining with the podocyte marker protein nephrin. Scale bar = 50 μm (×20); 75 μm (×100)
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transgene following differentiation at the non‐permissive 
temperature of 38°C and expressed typical podocyte marker 
proteins (Figure 4B). Using this in vitro system, we were able 
to generate podocytes with >95% knockdown of GSK3α 
(Figure 4C). Both conditionally immortalized GSK3α knock-
out podocytes (ciGSK3αKO) and non‐transduced control 
cells responded to insulin stimulation, significantly increasing 
phosphorylation of AKT at serine 473 and exhibiting similar 
levels of glucose uptake (Data not shown). However, there was 
no difference between control and knockout cells indicating 
that even near‐total knockdown of GSK3α expression did not 
improve podocyte insulin sensitivity (Figure 4D).
We also studied the dynamic regulation of mitogen‐ac-
tivated protein kinase (MAPK) ex‐vivo in the podocytes of 
F I G U R E  3  Podocyte‐specific knockdown of GSK3α does not ameliorate the progression of diabetic nephropathy in an streptozotocin (STZ) 
model of diabetes. A, Body weights in STZ‐treated (+STZ) and citrate buffer‐injected (−STZ) podGSK3αKD and control mice. One way ANOVA 
not significant, control mice n = 7, podGSK3αKD mice n = 9, citrate controls n = 3 for each genotype. B, Blood glucose measurements showing 
successful induction of STZ‐induced diabetes at 4 wk. STZ treated (+STZ); citrate controls (−STZ). One way ANOVA, ***P <0.001. C, Urinary 
albumin:creatinine in STZ‐treated (+STZ) and citrate buffer‐injected (−STZ) mice at 20 wk. One way ANOVA not significant, control mice n = 7, 
podGSK3αKD mice n = 9, citrate controls n = 3 for each genotype. D, Representative periodic acid Schiff staining and glomerulosclerosis index 
of STZ‐treated mice (+STZ) and citrate controls (−STZ) at 20 wk. Mild glomerulosclerosis observed in STZ‐treated animals (arrowed) but no 
difference between podGSK3αKD mice controls, one way ANOVA, *P <0.05, >30 glomeruli per mouse analyzed, three mice per group.
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podGSK3αKD and Cre negative control mice challenged 
with insulin after an overnight fast (Figure 4E). This con-
firmed that podGSK3αKD mice were able to phosphorylate 
MAPK in response to insulin but there did not appear to be 
any enhancement of this phosphorylation compared with 
podocyte GSK3α sufficient animals.
3.5 | Podocyte‐specific knockdown of 
GSK3α is not protective in in vivo and in vitro 
Adriamycin injury models
In light of previous studies showing the beneficial effects of 
both pharmacological inhibition of GSK3 and podocyte‐specific 
genetic GSK3β deletion in doxorubicin injury models,14-16 we 
hypothesized that isoform‐specific knockdown of GSK3α in 
podocytes might have similar protective effects. Adriamycin 
nephropathy, a model of podocyte injury, glomerulosclerosis 
and fibrosis 30 was induced in podGSK3αKD mice by a single 
tail vein injection at 12  mg/kg body weight when mice were 
8‐10 weeks of age and mice were monitored for 2 weeks be-
fore sacrifice. uACR was significantly increased at 2  weeks 
but no differences in albuminuria or body weight were appar-
ent between podGSK3αKD mice and control littermates (Figure 
5A,B).
To determine whether the increased GSK3α knockdown 
achieved in ciGSK3αKO cells would improve Adriamycin 
podocyte injury in vitro, we incubated cells with Adriamycin 
at 0, 0.25, 0.5 and 1 μg/mL for 24 hours. Both ciGSK3αKO 
and control cells looked unhealthy and were dying at an 
Adriamycin dose of 1  μg/mL (Figure 5C). Determination 
of cell number at Adriamycin concentrations of 0‐1 μg/mL 
using the non‐biased IN CELL computer‐based analyzer, 
confirmed that GSK3α deletion had no beneficial impact on 
cell survival (Figure 5D).
3.6 | Podocyte GSK3α knockdown 
is detrimental causing increased uACR 
in vivo and increased cell death with impaired 
autophagic flux in ciGSK3αKO cells
Although podGSK3αKD mice did not exhibit any overt 
phenotypic differences to controls with regard to body 
F I G U R E  5  Podocyte‐specific 
knockout of GSK3α is not protective in in 
vivo and in vitro Adriamycin injury models. 
A, Body weights of Adriamycin‐treated 
mice. (B) Urinary albumin:creatinine in 
Adriamycin‐treated mice showing increased 
albuminuria in both podGSK3αKD and 
control mice at 1 and 2 wk. t test **P <0.01. 
C, Representative images of ciGSK3αKO 
and non‐transduced control cells treated 
with Adriamycin for 24 h. D, Cell survival 
is identical in ciGSK3αKO and control cells 
treated with Adriamycin for 24 h. n = 3 
experiments
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weight and kidney histology (Figure S2A,C), we ob-
served a small but significantly increased basal uACR in 
podGSK3αKD mice at 6 weeks of age (Figure 6A; Figure 
S2B). We sought to further investigate the apparent det-
rimental effect of GSK3α reduction in podocytes by per-
forming in vitro studies on ciGSK3αKO cells. Although we 
did not see any evidence of podocyte loss in our mouse 
model (Figure S2D), a cell survival assay performed 7 days 
after gene knockout using our in vitro model showed a 25% 
rate of cell death in ciGSK3αKO cells when compared to 
controls (Figure 6B). GSK3α has been found to be a criti-
cal regulator of autophagy, and its loss in a mouse global 
knockout model results in accelerated senescence in multi-
ple tissues when aged.31 Previous studies have shown the 
importance of autophagy for podocyte homeostasis32-36 so 
we assessed autophagy in ciGSK3αKO cells. We observed 
that the polyubiquitin‐binding protein p62, which is de-
graded by autophagy, was increased in ciGSK3αKO cells 
(Figure 6C,D). However, although a higher basal level of 
p62 is suggestive of reduced autophagy in ciGSK3αKO 
cells, autophagy is a dynamic process and should be meas-
ured as a flux event. This can be represented by the dif-
ference in the amount of LC3II (which correlates with 
autophagosome number) in ciGSK3αKO and control cells 
in the presence or absence of the lysosomal inhibitor ba-
filomycin A1.19 We did not observe a clear band corre-
sponding to LC3I but it is known that the sensitivity of 
immunoblotting for LC3I is much lower than for LC3II and 
that differences in LC3II accumulation between samples 
is the most accurate way to assess autophagy by Western 
blot.19 Differences in the levels of p62 before and after ba-
filomycin exposure indicate the amount of p62 that would 
normally be degraded by autophagy in each cell type. 
Using this approach, we found that the levels of p62 deg-
radation (Figure 6E) and LC3II accumulation (Figure 6F) 
were significantly reduced in ciGSK3αKO cells indicative 
of impaired autophagic flux. We also assessed if enhancing 
autophagy in ciGSK3αKO cells by co‐incubating with the 
mTOR inhibitor Rapamycin would affect cell survival but 
did not find this to be the case (Figure S3).
4 |  DISCUSSION
We show here that in contrast to previous research indicating 
that podocyte‐specific genetic knockout of GSK3β has a ben-
eficial effect in models of kidney disease; podocyte ablation 
of GSK3α is not similarly protective. Our findings indicate 
that conversely, its loss is mildly detrimental revealing a role 
for the α isoform in podocyte homeostasis.
Mice with global knockout of GSK3α have been shown to 
have enhanced insulin sensitivity5 albeit in a strain‐dependent 
manner.8 We initially hypothesized that genetic knockdown 
of podocyte GSK3α might attenuate albuminuria in an STZ‐
induced model of diabetes due to increased podocyte insulin 
sensitivity. However, this was not the case.
In our animal model podocyte GSK3α expression was 
reduced by only approximately 50%, which we think was 
because our podocin Cre driver lost some of its Cre recom-
binase potency as a result of epigenetic silencing due to a 
high frequency of CpG dinucleotides.37 It is therefore pos-
sible that our in vivo results were due to incomplete gene 
knockdown. However it is important to remember that phar-
macological GSK3 inhibitors cause a reduction in activity 
of approximately 25%7 which suggests that our findings 
are clinically relevant. The limited level of GSK3α knock-
down in vivo led us to develop ciGSK3αKO podocytes with 
>95% gene knockout. However, we found that even this near 
complete knockdown of GSK3α in cultured podocytes did 
not elicit any increase in insulin sensitivity, consistent with 
our in vivo observations. Similarly, we did not observe any 
beneficial effect of podocyte GSK3α knockdown in in vivo 
and in vitro Adriamycin injury models contrary to results re-
ported using podocyte‐specific GSK3β knockout mice.13,14,38 
Our results suggest that GSK3α does not represent a poten-
tial target for augmentation of podocyte insulin signaling and 
that it is the reduction in GSK3β and not GSK3α activity 
that is responsible for the beneficial anti‐albuminuric and 
podocyte protective effects of pharmacological GSK3 inhib-
itors.13,15,16,39 We have recently shown that some GSK3 en-
zyme activity is critically important for podocyte and kidney 
function both developmentally and in maturity. When both 
mammalian GSK3 isoforms (α and β) are lost genetically, or 
sufficiently suppressed pharmacologically, it causes a severe 
phenotype.10 This is also the case when the GSK3 gene is lost 
in similar cells in other species including the nephrocyte of 
Drosophila.10
Because GSK3 inhibitors are not isoform selective, future 
work to elucidate the beneficial and detrimental signaling 
pathways differentially regulated by GSK3α and β may facil-
itate the identification of new drug targets for the treatment 
of albuminuric kidney disease lacking the deleterious side ef-
fects that result from excessive suppression of GSK3 activity.
Interestingly, we noted a mild but significant increase 
in albumniuria in podGSK3αKD mice and further in-
vestigated this apparent detrimental effect in vitro using 
ciGSK3αKO cells. We observed that 7  days after near 
complete knockout of GSK3α, podocytes were more 
susceptible to cell death providing further evidence that 
GSK3α has a role in podocyte homeostasis. Although we 
did not find evidence of similar podocyte loss in podG-
SK3αKD mice, this may be due to the much lower degree 
of gene knockdown in vivo (approximately 50%) com-
pared with the >95% GSK3α loss in ciGSK3αKO cells. 
Most GSK3 research has concentrated on the β isoform 
or the use of pharmacological GSK3 inhibitors and there 
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are few reports in the literature describing the effects of 
specific loss of GSK3α. The original study describing the 
generation of whole body GSK3α knockout mice5 found 
that such mice were viable with no adverse phenotype, 
however subsequently it has been shown that male mice 
lacking GSK3α in their testicular germ cells are sterile.40 
F I G U R E  6  Podocyte GSK3α knockdown is detrimental causing increased urinary albumin creatinine ratio in vivo and increased cell death 
with impaired autophagic flux in ciGSK3αKO cells. A, Urinary albumin:creatinine is increased in podGSK3αKD mice. Unpaired t test, *P < 0.05. 
n = 12‐13 mice per group. B, Cell survival assay showing 25% cell death in ciGSK3αKO podocytes 7 d after transduction when compared with 
untransduced control cells or Cre lenti transduced wild‐type podocytes. ANOVA with Tukey's post hoc test, **P < 0.01. wild‐type cells, n = 3, 
GSK3α floxed cells n = 6 experiments. C, Representative blots of ciGSK3αKO and control cells treated with bafilomycin A1 for 4 h.  
D, Densitometry showing increased basal expression of p62 in ciGSK3αKO cells. Unpaired t test, *P < 0.05 n = 3. E, Level of p62 degradation 
represented by the difference in p62 levels ± bafilomycin A1 in ciGSK3αKO and control cells. Unpaired t test, *P < 0.05 n = 4. F, Accumulation 
of LC3II represented by the difference in LC3II levels ± bafilomycin A1 in ciGSK3αKO and control cells. Unpaired t test, *P < 0.05 n = 3
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Additionally, a further recent elegant study of global 
GSK3α knockout mice has revealed that detrimental ef-
fects of GSK3α knockout become apparent as mice age. 
These mice had a reduced life span along with multiple 
age‐related pathologies attributable to a decreased level of 
autophagy.31 Autophagy, a conserved process that delivers 
proteins and damaged organelles to lysosomes for degra-
dation and turnover41 has been shown to be important in 
podocyte homeostasis. In common with other terminally 
differentiated cell types, podocytes have a high level of 
autophagy under basal conditions32 and impairment of this 
process has been implicated in podocyte damage associ-
ated with aging,35,42,43 diabetic nephropathy,34 mitochon-
drial dysfunction and FSGS.33 Conversely, enhancement 
of autophagic activity has a protective effect in models of 
glomerular disease.36,44 As global GSK3α knockout has 
been found to impair autophagy in multiple organ systems, 
we surmised that GSK3α knockout podocytes might also 
be autophagy deficient. We found this to be the case and 
that ciGSK3αKO podocytes had increased basal levels of 
p62 and reduced autophagic flux consistent with the cell 
death and increased albuminuria observed in our in vitro 
and in vivo podocyte GSK3α knockout models. We also 
assessed if impaired autophagy was directly linked to cell 
death in our knockout models by co‐incubating GSK3α 
knockout cells with the mTOR inhibitor Rapamycin but 
this did not have an effect in the short term. Going for-
ward it will be of interest to significantly age the podo-
cyte‐specific GSK3α mice, ideally using a Cre driver that 
is resistant to epigenetic degradation which has now been 
generated45 to assess for podocyte loss, glomerular disease 
and autophagocytic function. We speculate these would be 
abnormal.
In conclusion we have shown that partial or near‐total 
suppression of podocyte GSK3α is not protective in mod-
els of glomerular disease; its loss is, in fact, detrimental and 
is associated with impaired autophagic flux. This reveals a 
novel role for GSK3α in maintenance of podocyte function 
by promoting autophagy. Strategies to maintain or increase 
GSK3α activity may therefore represent a potential therapeu-
tic target in albuminuric kidney disease.
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